NASDAQ$BDTX
Black Diamond Therapeutics I · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Black Diamond Therapeutics I Q1 fiscal 2026: $0.00 revenue, $9.0M net loss
for the year ended December 31, 2025 (the Annual Report) and in other Securities and Exchange Commission (SEC) filings. (SEC accession 0001701541-26-000017)
- Revenue: $0.00
- Net loss: $9.0M
- Diluted EPS: $-0.16
- Operating income: $-11.3M
Headline financials
Revenue & EPS history
Black Diamond Therapeutics · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-1.4%
Avg return
Earnings day
-0.1%
Avg return
5 days after
-0.4%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+15.6%
Q4 2019
Best reaction
-19.6%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.5% | +0.0% | — | |
| Q4 2025 | +2.4% | -3.7% | +33.3% | |
| Q3 2025 | -8.1% | -1.5% | -31.4% | |
| Q1 2025 | +2.1% | +5.2% | +19.7% | |
| Q4 2024 | -1.8% | +4.1% | -15.8% | |
| Q3 2024 | +10.0% | +10.0% | -21.4% | |
| Q2 2024 | -14.0% | -12.5% | +5.3% | |
| Q1 2024 | -12.0% | -17.3% | -25.2% | |
| Q4 2023 | +4.8% | +19.7% | +39.3% | |
| Q3 2023 | -4.2% | -6.3% | +24.7% | |
| Q2 2023 | -3.5% | -9.7% | +2.3% | |
| Q1 2023 | -2.1% | -1.6% | +11.5% | |
| Q4 2022 | -19.6% | +3.6% | -3.0% | |
| Q3 2022 | -2.7% | +13.6% | -28.1% | |
| Q2 2022 | +4.5% | +4.3% | -21.8% | |
| Q1 2022 | -9.4% | -8.4% | +5.4% | |
| Q4 2021 | +8.2% | +7.8% | +16.4% | |
| Q3 2021 | +2.0% | -4.0% | -22.8% | |
| Q2 2021 | -1.8% | -1.3% | +4.3% | |
| Q1 2021 | -4.0% | +9.0% | -50.3% | |
| Q4 2020 | +2.1% | +0.7% | +19.0% | |
| Q3 2020 | +9.2% | +3.2% | +8.1% | |
| Q2 2020 | -9.2% | -11.4% | -11.6% | |
| Q1 2020 | -1.1% | -5.4% | -19.5% | |
| Q4 2019 | +15.6% | +0.4% | +51.7% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro